Product logins

Find logins to all Clarivate products below.


Polycystic Kidney Disease – Special Topics – Special Topic: Quantitative Physician Insights – US, EU5, Japan, China

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. The launch of Otsuka’s Jynarque / Jinarc / Samsca (tolvaptan) introduced the first disease-specific therapy for ADPKD. However, many opportunities remain for emerging ADPKD therapies owing to limitations of tolvaptan. For example, tolvaptan is not a disease-modifying therapy; its efficacy is considered moderate by thought-leaders interviewed; it is indicated only in adults who have rapidly progressing, or are at risk for, rapidly progressing ADPKD; and it is commonly associated with aquaretic adverse events. We examine how tolvaptan’s launch has impacted ADPKD patient treatment and the challenges / opportunities that emerging therapies will face entering this market.

QUESTIONS ANSWERED

  • How are patients diagnosed, categorized, and monitored? Is patient risk categorized? How frequently are patients monitored?
  • Which patients are prescribed tolvaptan? For which attributes do physicians think tolvaptan performs best / worst? How has tolvaptan’s launch affected the ADPKD treatment algorithm?
  • What are the greatest unmet needs in the treatment of ADPKD patients?
  • Based on four hypothetical drug product profiles, which attributes are most important to physicians’ prescribing decisions?

Geographies

  • United States, EU5 (France, Germany, Italy, Spain, United Kingdom), Japan, China

Primary research

  • Survey of 350 nephrologists: 50 China, 150 EU5 (30 each in France, Germany, Italy, Spain, United Kingdom), 100 United States, 50 Japan

Key drugs covered

  • Tolvaptan, emerging therapies

Key insights provided

  • Analysis of drug development opportunities
  • Factors influencing disease management and treatment decisions
  • Drivers and constraints of treatment selection
  • Physician-reported treatment practices
  • Rationale for changes in treatment approach
  • Physician-reported recent / anticipated changes in brand usage or treatment approach
  • Physician perceptions of unmet needs in the indication and related indications

PRODUCT DESCRIPTION

Special Topic: Quantitative Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…